Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Timothy M. Nywening(Washington University in St. Louis), Andrea Wang‐Gillam(Alvin J. Siteman Cancer Center), Dominic E. Sanford(Washington University in St. Louis), Brian A. Belt(University of Rochester Medical Center), Roheena Z. Panni(Washington University in St. Louis), Brian Cusworth(Alvin J. Siteman Cancer Center), Adetunji T. Toriola(Alvin J. Siteman Cancer Center), Rebecca Nieman(Washington University in St. Louis), Lori A. Worley(Washington University in St. Louis), Motoyo Yano(Alvin J. Siteman Cancer Center), Kathryn J. Fowler(Alvin J. Siteman Cancer Center), A. Craig Lockhart(Alvin J. Siteman Cancer Center), Rama Suresh(Alvin J. Siteman Cancer Center), Benjamin Tan(Washington University in St. Louis), Kian‐Huat Lim(Alvin J. Siteman Cancer Center), Ryan C. Fields(Alvin J. Siteman Cancer Center), Steven M. Strasberg(Washington University in St. Louis), William G. Hawkins(Alvin J. Siteman Cancer Center), David G. DeNardo(Alvin J. Siteman Cancer Center), S. Peter Goedegebuure(Alvin J. Siteman Cancer Center), David C. Linehan(University of Rochester Medical Center)
Cited by 773Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis